SEATTLE, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatments for cancers throughout the body, today announced the pricing of an underwritten offering of 39,576,088 shares of its common stock at an offering price of $3.79 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase 6,598,046 shares of its common stock at a price of $3.789 pe ...

Core Insights - The article emphasizes the value of in-depth analysis in the Biotech sector, highlighting the services offered by Biotech Analysis Central, which includes a model portfolio and extensive research articles [1][2]. Group 1: Company Overview - Biotech Analysis Central provides a subscription service that includes over 600 articles focused on Biotech investing, aimed at helping investors make informed decisions [2]. - The service offers a model portfolio consisting of more than 10 small and mid-cap stocks, each accompanied by detailed analysis [2]. Group 2: Subscription Details - The monthly subscription fee for Biotech Analysis Central is $49, with a yearly plan available at a discounted rate of $399, representing a 33.50% savings [1].

Panama's Supreme Court decision has strategic implications for the U.S., China and the fate of a $23 billion global ports deal ...

Core Viewpoint - The presentation at the 2026 JPMorgan Healthcare Conference highlights the commitment of Perceptive Therapeutics to patient-centered care, emphasizing the impact of their treatments on patients with serious conditions like neuroendocrine cancer [2][3]. Company Overview - Perceptive Therapeutics is focused on developing innovative treatments for patients with complex medical conditions, showcasing their dedication to improving patient outcomes [2]. - The company presented a case study of an elderly woman with neuroendocrine cancer who experienced tumor progression and was treated with their drug, VMT-alpha-NET, resulting in a significant reduction in tumor size after the first dose [3]. Industry Context - The healthcare industry is increasingly prioritizing patient outcomes and personalized medicine, as demonstrated by the case presented at the conference [2][3].

Summary of Perspective Therapeutics FY Conference Call Company Overview - **Company**: Perspective Therapeutics (NYSEAM:CATX) - **Industry**: Oncology, specifically focusing on radiopharmaceuticals Core Points and Arguments 1. **Patient-Centric Approach**: The CEO emphasized the importance of patient outcomes, sharing a case of an elderly woman with neuroendocrine cancer who showed significant tumor reduction after treatment with VMT Alphanet, highlighting the company's mission to transform patients' lives [2][3][4] 2. **Radiotherapy's Role in Oncology**: The company positions radiotherapy as a critical pillar in cancer treatment alongside chemotherapy and immunotherapy, advocating for the use of radiopharmaceuticals to target previously undruggable cancer cell surfaces [4][5] 3. **Innovative Drug Delivery**: Perspective Therapeutics utilizes a proprietary chemical chelator designed for superior biodistribution, allowing for targeted delivery of potent alpha particle payloads to cancer cells, which is more effective than traditional beta particles [5][6][9] 4. **Clinical Programs**: The company has three active clinical programs: - **VMT-NET**: Targeting neuroendocrine tumors, with a reported 39% overall response rate and 78% of patients remaining progression-free after one year [29][31] - **Melanoma Program**: Actively enrolling patients, focusing on combining treatments with checkpoint inhibitors [7][36] - **FAP-alpha Program**: Targeting a broad range of solid tumors, leveraging the stroma's role in tumor growth [39][40] 5. **Manufacturing Capabilities**: Perspective Therapeutics has established end-to-end manufacturing capabilities, ensuring a reliable supply chain for their isotopes and clinical products, which is crucial for timely patient treatment [25][26][57] 6. **Regulatory Progress**: The company has received fast-track designation from the FDA for its VMT-NET program and is moving towards registrational studies based on positive initial data [30][35] 7. **Financial Position**: As of the last quarterly filing, the company reported $174 million in cash, indicating a strong financial position to support ongoing and future clinical trials [44] 8. **Market Potential**: The company identifies a significant total addressable market in oncology for radiopharmaceuticals, citing existing successful products like Pluvicto and Lutathera, which generate billions in revenue [24][28] Additional Important Content 1. **Patient Selection and Imaging**: The use of Lead-203 for imaging tumors allows for better patient selection for therapies, enhancing treatment efficacy and safety [18][19] 2. **Safety Profile**: The company claims a best-in-class safety profile for its therapies, with no serious adverse events reported in recent trials, which is a significant differentiator from competitors [34][35] 3. **Community Engagement**: Positive feedback from clinicians and increased interest in the company's studies indicate a strong demand for their therapies within the medical community [47][49] 4. **Supply Chain Resilience**: The company has secured a robust supply chain for its isotopes, with the ability to stockpile parent isotopes, ensuring long-term operational stability [52][53] 5. **Future Data Updates**: The company plans to provide updates on its clinical programs throughout 2026, which will be critical for investor confidence and market positioning [45] This summary encapsulates the key points discussed during the conference call, highlighting the company's innovative approach, clinical progress, and market potential in the oncology sector.

Continued strong patient recruitment in neuroendocrine tumors for lead program VMT-α-NET sets the stage for submissions of robust clinical data package for presentation to more medical conferences in 2026, as well as regulatory engagementVMT-α-NET continues to be well-tolerated and shows durable disease control and deepening of tumor response with longer follow-up as reported at ASCO-GI 2026 Clinical updates expected in mid to late 2026 for VMT01 targeting melanoma and PSV359 targeting FAP across multiple ...

Clinical Trial Updates - Perspective Therapeutics, Inc. announced updated interim data from its Phase 1/2a clinical trial of [212Pb]VMT-α-NET for treating unresectable or metastatic neuroendocrine tumors[8] - The data presentation occurred at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium held from January 8-10, 2026[8]

Updated interim results with an additional ~13 weeks of follow-up since the prior update[212Pb]VMT-α-NET continues to be well-tolerated Updated efficacy analysis suggests durable disease control and deepening of tumor response per RECIST v1.1 in the first 23 patients in Cohort 2 and both patients in Cohort 1Objective response in 39% of patients in Cohort 2 regardless of SSTR2 expression profile, including one Cohort 2 patient who experienced an initial objective response pending confirmation since the prior ...

Core Viewpoint - Perspective Therapeutics, Inc. is advancing its radiopharmaceutical development for cancer treatments and will present at the upcoming J.P. Morgan Healthcare Conference [1][2]. Company Overview - Perspective Therapeutics, Inc. specializes in radiopharmaceuticals, focusing on innovative cancer treatments using proprietary technology that employs the alpha-emitting isotope Pb to target cancer cells [2]. - The company is developing complementary imaging diagnostics that utilize the same targeting moieties, enhancing personalized treatment and patient outcomes through a "theranostic" approach [2]. Clinical Programs - The company's clinical programs include neuroendocrine tumor (VMT-α-NET), melanoma (VMT01), and solid tumor (PSV359), which are currently in Phase 1/2a imaging and therapy trials in the U.S. [3]. - Perspective is expanding its regional network of drug product candidate finishing facilities, supported by its proprietary Pb generator, to provide patient-ready products for clinical trials and commercial operations [3].

Core Insights - Perspective Therapeutics, Inc. announced that updated data on its [Pb]VMT-α-NET program will be presented at the ASCO-GI Congress 2026, scheduled for January 8 to 10, 2026 [1][2] Group 1: Company Overview - Perspective Therapeutics is focused on developing advanced radiopharmaceutical treatments for various cancers, utilizing proprietary technology that employs the alpha-emitting isotope Pb to target cancer cells [4][5] - The company is conducting a multi-center, open-label, dose-escalation study of [Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors [3][4] Group 2: Clinical Data and Efficacy - As of the data cut-off date of September 12, 2025, safety findings from 55 patients indicated a favorable safety profile for [²¹²Pb]VMT-α-NET, with no dose-limiting toxicities or Grade 4 or 5 treatment-emergent adverse events reported [4][6] - Among 25 patients evaluated, 20 (80%) remained progression-free, and 8 patients achieved confirmed responses, all from Cohort 2, with a median follow-up of 41 weeks [6]